title: [A case report of severe hypo-phosphatemia due to paraneoplastic syndrome followed by severe hyper-phosphatemia due to tumor lysis syndrome after CHOP chemotherapy].
abstract: A 51-year-old man who underwent umbilical cord blood transplantation for acute lymphoblastic leukemia with a Philadelphia chromosome in April 2006 achieved complete remission. In June 2008, progressive renal dysfunction and melena emerged and the patient was diagnosed with B-cell-type malignant lymphoma. He presented with severe hypo-phosphate- mia(0. 1m g/dL)due to paraneoplastic syndrome, simultaneously. Because the development of tumor lysis syndrome followed by hyper-phophatemia was feared to occur after CHOP chemotherapy, we discontinued the adjustment of serum phosphorus. The serum phosphorus level was elevated to 11.6mg/dL after 3 days and decreased to 3. 8mg/dL after 5 days. We must be careful regarding hyper-phosphatemia and phosphorus adjustment even in patients with severe hypo-phosphatemia that is due to paraneoplastic syndrome.
authors.affiliation: Dept. of Pharmacy, Toranomon Hospital, Japan.
authors.forename: Tadaaki
authors.initials: T
authors.lastname: Ito
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Uchida
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Takagi
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Uchida
authors.forename: Shuichi
authors.initials: S
authors.lastname: Taniguchi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Hayashi
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010257:Paraneoplastic Syndromes / Q000097:blood*; D010710:Phosphates / Q000097:blood*; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D015275:Tumor Lysis Syndrome / Q000097:blood*; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D010710:Phosphates; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone